Communiqués Abbott Laboratories

Actions

ABT

US0028241000

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX Autres places de cotation 21:34:30 24/07/2026			Varia. 5j.	Varia. 1 janv.
103,10 ^USD	+2,33 %		+2,52 %	-17,62 %

08:42	Abivax étoffe sa direction commerciale
23/07	ABBOTT LABORATORIES : Daiwa Securities conserve son opinion neutre	ZM

Communiqués

17/07	Army integrating new handheld device to quickly assess brain injuries	AQ
16/07	Abbott Laboratories : ABT 2026 Q2 Exhibit 99.1 FINAL	PU
16/07	Abbott: Q2 Earnings Snapshot	AQ
16/07	Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance	PR
25/06	Court Considers Whether Growth Claims Were Tall Tales	AQ
25/06	Abbott hosts conference call for second-quarter earnings	PR
24/06	ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing	PR
23/06	New Similac(R) survey finds social media pressure to be 'perfect' is fueling a shift toward authenticity for the next generation of parents	AQ
22/06	New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents	PR
18/06	Big Claims, Little Kids: Recent SDNY Decision Highlights Risks In Advertising	AQ
12/06	Abbott declares 410th consecutive quarterly dividend	PR
08/06	New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers	PR
06/06	New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis	PR
27/05	Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes	PR
27/05	ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening	PR
26/05	Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026	PR
30/04	Abbott Laboratories : to highlight expanding cancer diagnostic portfolio and clinical evidence at Digestive Disease Week (DDW) 2026	PU
28/04	Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform	PR
25/04	Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026	PR
17/04	New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test	PR
16/04	Abbott: Q1 Earnings Snapshot	AQ
16/04	Abbott Laboratories : ABT 2026 Q1 Exhibit 99.1 FINAL	PU
16/04	Abbott Laboratories : Q1 2026 Earnings Infographic	PU
16/04	Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences	PR
13/04	Illinois Jury Awards Four Families $70 Million in Verdict Against Baby Formula Manufacturer	AQ